4.8 Article

Synthesis of the GPR40 Partial Agonist MK-8666 through a Kinetically Controlled Dynamic Enzymatic Ketone Reduction

Journal

ORGANIC LETTERS
Volume 18, Issue 22, Pages 5888-5891

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/acs.orglett.6b02910

Keywords

-

Ask authors/readers for more resources

A scalable and efficient synthesis of the GPR40 agonist MK-8666 was developed from a simple pyridine building block. The key step to set the stereochemistry at two centers relied on an enzymatic dynamic kinetic reduction of an unactivated ketone. Directed evolution was leveraged to generate an optimized ketoreductase that provided the desired trans alcohol in >30:1 dr and >99% ee. Further, it was demonstrated that all four diastereomers of this hydroxy-ester could be prepared in high yield and selectivity. Subsequently, a challenging intramolecular displacement was carried out to form the cyclopropane ring system with perfect control of endo/exo selectivity. The endgame coupling strategy relied on a Pd-catalyzed C-O coupling to join the headpiece chloropyridine with the benzylic alcohol tailpiece.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Biochemistry & Molecular Biology

Fibrils Colocalize Caspase-3 with Procaspase-3 to Foster Maturation

Julie A. Zorn, Dennis W. Wolan, Nicholas J. Agard, James A. Wells

JOURNAL OF BIOLOGICAL CHEMISTRY (2012)

Article Medicine, Research & Experimental

High-throughput screening of antibody variants for chemical stability: identification of deamidation-resistant mutants

Danielle M. DiCara, Nisana Andersen, Ruby Chan, James A. Ernst, Gai Ayalon, Greg A. Lazar, Nicholas J. Agard, Amy Hilderbrand, Isidro Hotzel

Article Biochemical Research Methods

Inflammatory Stimuli Regulate Caspase Substrate Profiles

Nicholas J. Agard, David Maltby, James A. Wells

MOLECULAR & CELLULAR PROTEOMICS (2010)

Article Biochemical Research Methods

The DegraBase: A Database of Proteolysis in Healthy and Apoptotic Human Cells

Emily D. Crawford, Julia E. Seaman, Nick Agard, Gerald W. Hsu, Olivier Julien, Sami Mahrus, Huy Nguyen, Kazutaka Shimbo, Hikari A. I. Yoshihara, Min Zhuang, Robert J. Chalkley, James A. Wells

MOLECULAR & CELLULAR PROTEOMICS (2013)

Article Biochemistry & Molecular Biology

Unraveling the mechanism of cell death induced by chemical fibrils

Olivier Julien, Martin Kampmann, Michael C. Bassik, Julie A. Zorn, Vincent J. Venditto, Kazutaka Shimbo', Nicholas J. Agard, Kenichi Shimada, Arnold L. Rheingold, Brent R. Stockwell, Jonathan S. Weissman, James A. Wells

NATURE CHEMICAL BIOLOGY (2014)

Article Multidisciplinary Sciences

Global kinetic analysis of proteolysis via quantitative targeted proteomics

Nicholas J. Agard, Sami Mahrus, Jonathan C. Trinidad, Aenoch Lynn, Alma L. Burlingame, James A. Wells

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)

Article Medicine, Research & Experimental

Preclinical optimization of Ly6E-targeted ADCs for increased durability and efficacy of anti-tumor response

Josefa Dela Cruz Chuh, MaryAnn Go, Yvonne Chen, Jun Guo, Hanine Rafidi, Danielle Mandikian, Yonglian Sun, Zhonghua Lin, Kellen Schneider, Pamela Zhang, Rajesh Vij, Danielle Sharpnack, Pamela Chan, Cecile de la Cruz, Jack Sadowsky, Dhaya Seshasayee, James T. Koerber, Thomas H. Pillow, Gail D. Phillips, Rebecca K. Rowntree, C. Andrew Boswell, Katherine R. Kozak, Andrew G. Polson, Paul Polakis, Shang-Fan Yu, Peter S. Dragovich, Nicholas J. Agard

Summary: Early success with brentuximab vedotin in treating classical Hodgkin lymphoma led to the development of multiple MMAE antibody-drug conjugates, but most of these have not been successful in clinical trials. This study describes the development of second-generation therapeutic ADCs targeting Ly6E, with a focus on using DNA-damaging agents to improve durability of response. The new ADCs showed promising preclinical efficacy in driving tumor regression and reducing the likelihood of resistance compared to traditional MMAE-based conjugates.
Article Hematology

Cleavage of talin by calpain promotes platelet-mediated fibrin clot contraction

Karen P. Fong, Kathleen S. Molnar, Nicholas Agard, Rustem Litvinov, Oleg Kim, James A. Wells, John W. Weisel, William F. DeGrado, Joel S. Bennett

Summary: Blood clot contraction is driven by traction forces generated by the platelet cytoskeleton and regulated by integrin alpha IIb beta 3. Proteolytically cleaved platelet proteins, particularly talin and vinculin, play crucial roles in clot contraction. Calpain-mediated cleavage of these proteins occurs independent of cytoskeletal-generated tensile forces, suggesting calpain's involvement in later stages of clot retraction through focal adhesion disassembly.

BLOOD ADVANCES (2021)

Article Medicine, Research & Experimental

Generation of a Porcine Antibody Fab Fragment Using Protein Engineering to Facilitate the Evaluation of Ocular Sustained Delivery Technology

Robert F. Kelley, Devin B. Tesar, Yue Wang, Nicholas J. Agard, Patrick G. Holder, Joyce Chan, Laetitia Comps-Agrar, Judit Horvath, Joshua D. Horvath, Susan R. Crowell

Summary: Researchers have successfully developed a stable surrogate molecule for testing ocular drug delivery systems in a porcine model, which has low porcine immunogenicity and can continuously release the drug.

MOLECULAR PHARMACEUTICS (2022)

Article Medicine, Research & Experimental

Development of T-cell engagers selective for cells co-expressing two antigens

Danielle M. Dicara, Sunil Bhakta, Mary Ann Go, James Ziai, Ron Firestein, Bill Forrest, Chen Gu, Steven R. Leong, Genee Lee, Shang-Fan Yu, Andrew G. Polson, Nicholas J. Agard

Summary: T cell-engaging bispecific antibodies (TCEs) have shown clinical effectiveness in treating hematological cancers, but their use in solid tumors can cause toxicity in normal tissues. This study developed TCEs that preferentially induce T cell-mediated death in target cells co-expressing two tumor-associated antigens, aiming to improve safety and efficacy.
Article Multidisciplinary Sciences

Antibody targeting of E3 ubiquitin ligases for receptor degradation

Hadir Marei, Wen-Ting K. Tsai, Yee-Seir Kee, Karen Ruiz, Jieyan He, Chris Cox, Tao Sun, Sai Penikalapati, Pankaj Dwivedi, Meena Choi, David Kan, Pablo Saenz-Lopez, Kristel Dorighi, Pamela Zhang, Yvonne T. Kschonsak, Noelyn Kljavin, Dhara Amin, Ingrid Kim, Andrew G. Mancini, Thao Nguyen, Chunling Wang, Eric Janezic, Alexander Doan, Elaine Mai, Hongkang Xi, Chen Gu, Melanie Heinlein, Brian Biehs, Jia Wu, Isabelle Lehoux, Seth Harris, Laetitia Comps-Agrar, Dhaya Seshasayee, Frederic J. de Sauvage, Matthew Grimmer, Jing Li, Nicholas J. Agard, Felipe de Sousa e Melo

Summary: The study presents a strategy utilizing PROTABs technology to achieve target degradation advantages, enabling tissue-selective degradation of cell-surface receptors. By optimizing antibody formats, this technology can facilitate 'on-demand' degradation.

NATURE (2022)

Article Ophthalmology

Direct Tie2 Agonists Stabilize Vasculature for the Treatment of Diabetic Macular Edema

Nicholas J. Agard, Gu Zhang, John Ridgeway, Danielle M. Dicara, Phillip Y. Chu, Rachana Ohri, Sarah Sanowar, Jean-Michel Vernes, Hannah Chi, Jiameng Zhang, Emily Holz, Maciej Paluch, Guannan He, Yingjia Benson, Jianhuan Zhang, Pamela Chan, Nga Tang, Prachi Javale, Blair Wilson, Kathy Barrett, Rebecca K. Rowntree, Julie Hang, Y. Gloria Meng, Phil Hass, Germaine Fuh, Robert Piskol, Vladimir Bantseev, Kelly M. Loyet, John C. Tran, Cong Wu, Vahan B. Indjeian, Vittal Shivva, Minhong Yan

Summary: This study explores a potential therapeutic approach for the treatment of DME by directly activating the Tie2 pathway to reduce vascular leakage, leading to the reduction of edema and improvement of vision.

TRANSLATIONAL VISION SCIENCE & TECHNOLOGY (2022)

Article Multidisciplinary Sciences

Optimizing human & alpha;-galactosidase for treatment of Fabry disease

William C. Hallows, Kristen Skvorak, Nick Agard, Nikki Kruse, Xiyun Zhang, Yu Zhu, Rachel C. Botham, Chinping Chng, Charu Shukla, Jessica Lao, Mathew Miller, Antoinette Sero, Judy Viduya, Moulay Hicham Alaoui Ismaili, Kerryn McCluskie, Raphael Schiffmann, Adam P. Silverman, Jin-Song Shen, Gjalt W. Huisman

Summary: Fabry disease is caused by a deficiency of α-galactosidase A (GLA), resulting in the accumulation of glycosphingolipids. Directed evolution was used to generate more stable GLA variants, such as GLAv05 and GLAv09, which showed improved stability, enzyme activity, and pharmacokinetics. These findings hold promise for more effective treatments of lysosomal storage diseases.

SCIENTIFIC REPORTS (2023)

Article Medicine, Research & Experimental

Targeted IgMs agonize ocular targets with extended vitreal exposure

Yvonne Chen, Maciej Paluch, Julie A. Zorn, Sharmila Rajan, Brandon Leonard, Alberto Estevez, John Brady, Henry Chiu, Wilson Phung, Amin Famili, Minhong Yan, Claudio Ciferri, Marissa L. Matsumoto, Greg A. Lazar, Susan Crowell, Phil Hass, Nicholas J. Agard

No Data Available